Cargando...
Registries supporting new drug applications
PURPOSE: Knowledge of the benefits and risks of new drugs is incomplete at the time of marketing approval. Registries offer the possibility for additional, post‐approval, data collection. For all new drugs, which were approved in the European Union between 2007 and 2010, we reviewed the frequency, t...
Gardado en:
| Publicado en: | Pharmacoepidemiol Drug Saf |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5725674/ https://ncbi.nlm.nih.gov/pubmed/28983992 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pds.4332 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|